Pulmonary lymphangioleiomyomatosis: a rare and challenging case report with unusual presentation of human melanoma black-45
DOI:
https://doi.org/10.18203/2320-6012.ijrms20253632Keywords:
HMB45, Lymphangioleiomyomatosis, Lung cystic disease, mTORAbstract
Lymphangioleiomyomatosis (LAM) is a very rare disease that generally affects young women of reproductive health group. It is characterized by abnormal proliferation of smooth muscle like cells (LAM cells) in the lungs (pulmonary LAM) and extrapulmonary sites (extrapulmonary LAM). Patients usually present with spontaneous pneumothorax, hemoptysis and progressive dyspnea. There is a poor awareness, knowledge and records about this disease making it a difficult diagnosis. Herein this report presents a case of pulmonary LAM in a 63 years old female with h/o dyspnea and chest pain. Her imaging studies showed fibrosis and nodular lesions in both lungs suggesting metastatic lesions. Later on, after a lung biopsy the diagnosis of lymphangioleiomyomatosis was given and immunohistochemical staining was positive for spinal muscular atrophy (SMA), CD34 and negative for human melanoma black-45 (HMB45). HMB45 negative PLAM is very rare with only few instances in the literature making it a difficult diagnosis. Our patient was given mTOR inhibitors along with supportive and conservative management and she responded well to the treatment. This rare cystic lung disease can be devastating as it causes progressive lung damage. Limited options in the management of PLAM makes early diagnosis as key and there is also a need for high index suspicion with cystic lung disease in women.
Metrics
References
Harknett EC, Chang WY, Byrnes S, Johnson J, Lazor R, Cohen MM, et al. Use of variability in national and regional data to estimate the prevalence of lymphangioleiomyomatosis. QJM. 2011;104(11):971-9. DOI: https://doi.org/10.1093/qjmed/hcr116
Hohman DW, Noghrehkar D, Ratnayake S. Lymphangioleiomyomatosis: A review. Eur J Intern Med. 2008;19(5):319-24. DOI: https://doi.org/10.1016/j.ejim.2007.10.015
Verma SK, Verma SK. Pulmonary lymphangioleiomyomatosis (PLAM). Lung India. 2007;24(4):150-2. DOI: https://doi.org/10.4103/0970-2113.44382
Moss J, Avila NA, Barnes PM, Litzenberger RA, Bechtle J, Brooks PG, et al. Prevalence and clinical characteristics of lymphangioleiomyomatosis (LAM) in patients with tuberous sclerosis complex. Am J Respir Crit Care Med. 2001;164(4):669-71. DOI: https://doi.org/10.1164/ajrccm.164.4.2101154
Krymskaya VP. Smooth muscle like cells in pulmonary lymphangioleiomyomatosis. Proc Am Thorac Soc. 2008;5:119-26. DOI: https://doi.org/10.1513/pats.200705-061VS
Taveira-DaSilva AM, Moss J. Epidemiology, pathogenesis and diagnosis of lymphangioleiomyomatosis. Expert Opin Orphan Drugs. 2016;4:369-78. DOI: https://doi.org/10.1517/21678707.2016.1148597
Glasgow CG, Avila NA, Lin JP, Stylianou MP, Moss J. Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement. Chest. 2009;135(5):1293-300. DOI: https://doi.org/10.1378/chest.08-1160
Johnson SR, Cordier JF, Lazor R, Cottin V, Costabel U, Harari S, et al. European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. Eur Respir J. 2010;35(1):14-26. DOI: https://doi.org/10.1183/09031936.00076209